Premium
Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight‐Control Clinical Trial and an Observational Cohort
Author(s) -
Coates Laura C.,
Tillett William,
Shaddick Gavin,
Pincus Theodore,
Kavanaugh Arthur,
Helliwell Philip S.
Publication year - 2018
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.23460
Subject(s) - psoriatic arthritis , medicine , observational study , cohort , visual analogue scale , rheumatoid arthritis , physical therapy , arthritis
Objective To analyze the Routine Assessment of Patient Index Data 3 ( RAPID 3), a patient‐reported, composite index, designed initially for feasibility in clinical care. RAPID 3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID 3 in patients with psoriatic arthritis (PsA). Methods Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis ( TICOPA ) clinical trial, and the Long‐Term Outcome in Psoriatic Arthritis Study ( LOPAS II ), an observational cohort. RAPID 3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale ( VAS ), and global VAS . RAPID 3 scores were compared to the Psoriatic Arthritis Disease Activity Score ( PASDAS ), the Disease Activity in Psoriatic Arthritis ( DAPSA ), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM , smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID 3 remission was compared to criteria for both standard minimal disease activity ( MDA ) and very low disease activity ( VLDA ). Results RAPID 3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID 3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS ( P < 0.01). RAPID 3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion RAPID 3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.